Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
p21 is induced by and mediates the effects of
p53
in response to DNA damage arresting the cell in G1 or G2, by inhibiting multiple cyclin-cyclin-dependent kinases (CDK) or binding to proliferating-cell nuclear antigen (PCNA), respectively. To determine whether p21 mutants occur in tumors we examined DNA from 188 primary non-Hodgkin's B-cell lymphoma (NHL) tumors and 84 chronic myelogenous leukemia samples for mutational changes in the coding region of p21 by single-strand conformation polymorphism (SSCP) analysis and direct sequencing of polymerase chain reaction (PCR)-amplified DNA. We did not find mutations in the coding region in these two tumor types. We identified a polymorphic nucleotide change in codon 31 in which a transversion from C to A substituted amino acid arginine for serine. Three of 188 NHL tumors were homozygous for this change, but they were not identified in 84 CMLs or in 97 normal controls. On the other hand, in one CML case a transition from G to A in codon 64 substituted amino acid threonine for
alanine
. These data do not indicate that derangements in the coding region of p21 contribute to the initiation and/or progression of these tumors.
...
PMID:Absence of somatic changes in p21 gene in non-Hodgkin's lymphoma and chronic myelogenous leukemia. 865 61
Mutations in
p53
, a tumor suppressor gene, are one of the most common genetic lesions of human cancers. The relationship between
p53
gene mutation and ultraviolet (UV) light has been demonstrated in skin cancers of sun-exposed sites. In this study, genomic DNA from 12 skin cancers was screened for mutations in exons 5 to 9 of this gene using the polymerase chain reaction--single strange configuration polymorphism (PCR-SSCP) analysis followed by DNA sequencing. DNA samples were obtained from 8 basal cell carcinomas (BCCs): 1 from an organoid nevus, 1 from a patient with basal cell nevus syndrome, 1 from a patient with xeroderma pigmentosum, and 1 from a recurrent and 4 from primary sporadic lesions on actinic damaged skin, and from 4 squamous cell carcinomas (SCCs): 1 from a burn scar, 1 from a patient with epidermodysplasia verruciformis, and 2 from actinic keratosis. Mutation of the
p53
gene was detected in only 1 case of SCC which had arisen from actinic keratosis. The mutation occurred at codon 159 in exon 5 with a GCC to CCC base-pair substitution resulting in an amino acid change of
alanine
to proline. This mutation does not correspond to results of UV mutagenesis studies reported in the literature. Our findings imply that, although
p53
gene mutation and UV exposure play an important role in the carcinogenesis of some skin cancers, they are not crucial, especially in skin cancers that develop from underlying skin disorders.
...
PMID:p53 gene mutations in skin cancers with underlying disorders. 866 19
Human wild-type (wt)
p53
can induce apoptosis in transiently transfected H1299 cells maintained at 37 degrees C, whereas tumor-derived mutant forms of
p53
(with the mutation Ala-143, His-175, or Trp-248) fail to do so. At 37 degrees C,
p53
with a mutation to
Ala
at amino acid 143 (p53Ala143) was transcriptionally inactive. However, at 32 degrees C, p53Ala143 strongly activated transcription from several physiologically relevant
p53
-responsive promoters, to extents similar or greater than that of wt
p53
. Unexpectedly, p53Ala143 was defective in inducing apoptosis in H1299 cells at 32 degrees C. Concomitantly with the loss of apoptotic activity, p53Ala143 was found to be deficient in its ability to activate transcription from the
p53
-responsive portions of the Bax and insulin-like growth factor-binding protein 3 gene promoters. It is proposed that there may exist distinct classes of
p53
-responsive promoters, whose ability to be activated by
p53
can be regulated differentially. Such differential regulation may have functional consequences for the effects of
p53
on cell fate.
...
PMID:A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. 875 55
The 289-residue (289R) and 243R early region 1A (E1A) proteins of human adenovirus type 5 induce cell transformation in cooperation with either E1B or activated ras. Here we report that Ser-132 in both E1A products is a site of phosphorylation in vivo and is the only site phosphorylated in vitro by purified casein kinase II. Ser-132 is located in conserved region 2 near the primary binding site for the pRB tumor suppressor and, in 289R, just upstream of the conserved region 3 transactivation domain involved in regulation of early viral gene expression. Mutants containing
alanine
or glycine in place of Ser-132 interacted with pRB-related proteins at somewhat reduced efficiency; however, all Ser-132 mutants transformed primary rat cells in cooperation with E1B as well as or better than the wild type when both major E1A proteins were expressed. Such was not the case with mutants expressing only 289R. In cooperation with E1B, the Asp-132 and Gly-132 mutants yielded reduced numbers of smaller transformed foci. With activated ras, all Ser-132 mutants were significantly defective for transformation and the rare foci produced were small and contained extensive areas populated by low densities of flat cells. In the absence of E1B, all Ser-132 mutants induced
p53
-independent cell death more readily than virus expressing wild-type 289R. These results suggested that phosphorylation at Ser-132 may enhance the binding of pRB and related proteins and also reduce the toxicity of E1A 289R, thus increasing transforming activity.
...
PMID:Importance of the Ser-132 phosphorylation site in cell transformation and apoptosis induced by the adenovirus type 5 E1A protein. 876 48
We have examined in detail the DNA binding properties of several immunopurified tumor-derived mutant p53 proteins (Val-143 -->
Ala
, Arg-175 --> His, Arg-248 --> Trp, Arg-249 --> Ser, and Arg-273 --> His). While all mutants were defective for binding to DNA at 37 ;C, each bound specifically to several cognate
p53
binding sites at sub-physiological temperatures (25-33 ;C), and several mutants activated transcription from a
p53
-responsive promoter at 26 degrees C in transfected H1299 cells. Heating mutant p53 proteins at 37 degrees C irreversibly destroyed their ability to subsequently bind at 25 degrees C. However, several different monoclonal antibodies that each share the ability to recognize an epitope encompassing amino acids 46-55 markedly stabilized binding by mutant p53 proteins at 37 degrees C. Both intact antibody and FAb fragments allowed mutant p53 to bind to DNA. By contrast, antibodies that recognize epitopes located elsewhere within
p53
stabilized mutant p53 binding significantly less effectively. Our data show that the major hot-spot
p53
mutants have the intrinsic ability to bind to DNA and that a unique region within the N terminus of
p53
may be critical for rescuing them from loss of binding at physiological temperatures. This suggests the possibility of developing small molecules that can stabilize mutant p53 proteins under physiological conditions.
...
PMID:Regulation of mutant p53 temperature-sensitive DNA binding. 881 Mar 17
Transgenic mice expressing excess metallothionein-I and SV-40 T-antigen were generated to test the hypothesis that metallothionein may influence the rate of neoplastic transformation induced by T-antigen within the liver. The livers of the double transgenic mice grew at the same rate (to 32% body weight), had similar morphological and histological appearance, had similar chromosomal instability, and released identical amounts of serine and
alanine
aminotransferases into the blood as mice bearing SV-40 T-antigen alone, despite the fact that metallothionein levels were elevated five- to ten-fold. We conclude that elevated levels of metallothionein-I do not influence either the initial hyperplasia or the subsequent neoplastic transformation that is induced by T-antigen, which is thought to act by sequestering the
P53
and retinoblastoma gene products.
...
PMID:Transformation of liver by SV-40 T-antigen in transgenic mice is unaffected by metallothionein. 882 56
To study the importance of phosphorylation for
p53
transactivation function, we generated mutations at each of its known phosphorylated serine amino acids. Mutations of murine
p53
serine residues individually to either
alanine
or glutamic acid at positions 7, 9, 12, 18, 37, 312, and 389 resulted in equivalent levels of transcriptional activation in standard transient transfection experiments. However, when
p53
transcriptional activity was measured in cells that attain G1 arrest upon contact inhibition, wild-type
p53
was inactive, and only alteration at serine 389 to glutamic acid resulted in a functional
p53 protein
. This Ser --> Glu mutant also has an increased ability to bind DNA. Elimination of the phosphorylation site by substitution of an
alanine
amino acid resulted in loss of transcriptional activity. We also demonstrated that specific phosphorylation of
p53
at serine 389 is induced by cyclin E overexpression in high-density cells. Our data establish for the first time that phosphorylation of
p53
at serine 389 is important in activating its function in vivo.
...
PMID:Mutation of phosphoserine 389 affects p53 function in vivo. 891 Jun 2
The
p53
gene regulates the G1 cell cycle checkpoint in response to DNA damage. A primary murine mesothelial cell line (D9) spontaneously acquired a point mutation at codon 135 in exon 5 of the
p53
gene, resulting in substitution of
alanine
for proline; early passage D9 cells expressed wild-type
p53
. The growth rate of late passage D9 cells that acquired the
p53
mutation was increased compared to that of early passage cells; however, this mutation was not sufficient to confer tumorigenicity to this cell line. Mammalian cells that express wild-type
p53
show a transient arrest in G1 after exposure to ionizing radiation. Early passage D9 cells showed a G1 arrest following ionizing radiation, while late passage D9 cells arrested in G2 or mitosis. The clastogenic effects of ionizing radiation can be demonstrated by the cytokinesis-arrested micronucleus assay. Following treatment with cytochalasin B to arrest cytokinesis, ionizing radiation induced micronuclei in 50% of late passage D9 cells compared to 15% of early passage cells. After exposure to 15 micrograms/cm2 of crocidolite asbestos fibers, 18% of late passage cells had micronuclei compared to 4% of early passage cells. It is hypothesized that loss of the G1 cell cycle checkpoint contributes to genetic instability in murine mesothelial cells.
...
PMID:Spontaneous p53 mutation in murine mesothelial cells: increased sensitivity to DNA damage induced by asbestos and ionizing radiation. 891 99
With the use of clonogenic survival assays, we show that wild-type
p53
-expressing A2780 human ovarian cell lines transfected with a dominant negative mutant p53 gene (codon 143, valine to
alanine
) acquired cross-resistance to ionizing radiation, cisplatin, doxorubicin, and 1-beta-D-arabinofuranosylcytosine. However, these mutant p53-transfected cell lines retained sensitivity to taxol and camptothecin. We also show that immature thymocytes from mice with the
p53
gene genetically inactivated showed reduced ability to undergo apoptosis after treatment with ionizing radiation and cisplatin compared with wild-type mice. However, taxol-induced apoptosis in thymocytes does not seem to be dependent on
p53
status. Camptothecin also induced apoptosis in a
p53
-independent manner in thymocytes at low doses but in a
p53
-dependent manner at high doses. These data suggest that taxoids and camptothecin analogs could have activity in tumors that have aberrant
p53
function and provide a rationale for the clinical observations of responsiveness of refractory ovarian cancer to these drugs.
...
PMID:Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. 896 75
The adenovirus type 5 55-kDa E1B protein (E1B-55kDa) cooperates with E1A gene products to induce cell transformation. E1A proteins stimulate DNA synthesis and cell proliferation; however, they also cause rapid cell death by
p53
-dependent and
p53
-independent apoptosis. It is believed that the role of the E1B-55kDa protein in transformation is to protect against
p53
-dependent apoptosis by binding to and inactivating
p53
. It has been shown previously that the 55-kDa polypeptide abrogates
p53
-mediated transactivation and that mutants defective in
p53
binding are unable to cooperate with E1A in transformation. We have previously mapped phosphorylation sites near the carboxy terminus of the E1B-55kDa protein at Ser-490 and Ser-491, which lie within casein kinase II consensus sequences. Conversion of these sites to
alanine
residues greatly reduced transforming activity, and although the mutant 55-kDa protein was found to interact with
p53
at normal levels, it was somewhat defective for suppression of
p53
transactivation activity. We now report that a nearby residue, Thr-495, also appears to be phosphorylated. We demonstrate directly that the wild-type 55-kDa protein is able to block E1A-induced
p53
-dependent apoptosis, whereas cells infected by mutant pm490/1/5A, which contains
alanine
residues at all three phosphorylation sites, exhibited extensive DNA fragmentation and classic apoptotic cell death. The E1B-55kDa product has been shown to exhibit intrinsic transcriptional repression activity when localized to promoters, such as by fusion with the GAL4 DNA-binding domain, even in the absence of
p53
. Such repression activity was totally absent with mutant pm490/1/5A. These data suggested that inhibition of
p53
-dependent apoptosis may depend on the transcriptional repression function of the 55-kDa protein, which appears to be regulated be phosphorylation at the carboxy terminus.
...
PMID:Regulation of p53-dependent apoptosis, transcriptional repression, and cell transformation by phosphorylation of the 55-kilodalton E1B protein of human adenovirus type 5. 909 35
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>